Arcturus Therapeutics Holdings Inc. (ARCT) vs Relmada Therapeutics, Inc. (RLMD)

Arcturus Therapeutics Holdings Inc. and Relmada Therapeutics, Inc. are both Biotechnology companies. Arcturus Therapeutics Holdings Inc. and Relmada Therapeutics, Inc. are of similar size ($412.4M and $406.4M). Relmada Therapeutics, Inc. has the higher net margin (0.00% vs −317.6%) and the higher return on invested capital (0.00% vs 0.00%). Across the 12 metrics below, Relmada Therapeutics, Inc. leads on 8 and Arcturus Therapeutics Holdings Inc. on 4.

Valuation

Metric ARCT RLMD Biotechnology median
P/E n/m n/m 7.88
P/S 13.40 n/m 11.47
P/B 2.29 2.08 2.52
Price to free cash flow n/m n/m 21.16
EV/EBITDA n/m n/m 0.74
EV/Sales 7.54 n/m 10.73
Earnings yield (23.90%) (23.50%) (28.84%)
Free cash flow yield (18.49%) (29.59%) (23.03%)

Profitability

Metric ARCT RLMD Biotechnology median
Gross margin 100.00% 0.00% 65.16%
Operating margin (348.32%) 0.00% 0.00%
Net margin (317.61%) 0.00% 0.00%
Free cash flow margin (247.79%) 0.00% 0.00%
Return on equity (46.31%) (55.66%) (57.72%)
Return on assets (34.96%) (51.57%) (49.22%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric ARCT RLMD Biotechnology median
Revenue growth (TTM) (75.95%) — 5.64%
EPS growth (last fiscal year) 20.00% 45.28% —
Revenue growth, 5-year CAGR 53.78% — 8.40%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric ARCT RLMD Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 5.88 29.52 4.73
Net debt to EBITDA 3.15 1.57 0.96

Dividend

Metric ARCT RLMD Biotechnology median
Dividend yield — — 2.10%
Payout ratio 0.00 0.00 0.00

Size

Metric ARCT RLMD Biotechnology median
Market cap 412.41m 406.41m 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack